REFERENCES
1. Kyritsis A. Evaluation and treatment of CNS neoplasms. In: Lechtenberg R, Schutta HS, editors. Neurology Practice Guidelines New York: Marcel Dekker; 1998. pp. 473-96.
2. Kyritsis AP, Levin VA. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 2011;67:971-83.
3. Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK. Response and progression in recurrent malignant glioma. Neuro Oncol 1999;1:282-8.
4. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-8.
5. Zikou AK, Alexiou GA, Kosta P, Goussia A, Astrakas L, Tsekeris P, Voulgaris S, Malamou Mitsi V, Kyritsis AP, Argyropoulou MI. Diffusion tensor and dynamic susceptibility contrast MRI in glioblastoma. Clin Neurol Neurosurg 2012;114:607-12.
6. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro Oncology (RANO) Working Group. Neurosurgery 2012;70:234-43.
7. Nowosielski M, Recheis W, Goebel G, Güler O, Tinkhauser G, Kostron H, Schocke M, Gotwald T, Stockhammer G, Hutterer M. ADC histograms predict response to anti angiogenic therapy in patients with recurrent high grade glioma. Neuroradiology 2011;53:291-302.
8. Mariani G, Bruselli L, Kuwert T, Kim EE, Flotats A, Israel O, Dondi M, Watanabe N. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging 2010;37:1959-85.
9. Okajima K, Ohta Y. Diagnostic imaging of high grade astrocytoma: heterogeneity of clinical manifestation, image characteristics, and histopathological findings. Brain Nerve 2012;64:1151-7.
10. Alexiou GA, Tsiouris S, Voulgaris S, Kyritsis AP, Fotopoulos AD. Glioblastoma multiforme imaging: the role of nuclear medicine. Curr Radiopharm 2012;5:308-13.
11. Alexiou GA, Tsiouris S, Kyritsis AP, Fotakopoulos G, Goussia A, Voulgaris S, Fotopoulos AD. The value of 99mTc tetrofosmin brain SPECT in predicting survival in patients with glioblastoma multiforme. J Nucl Med 2010;51:1923-6.
12. Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet Boucard C, Tabouret E, Mundler O, Figarella Branger D, Guedj E. FDG PET predicts survival in recurrent high grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol 2012;14:649-57.
13. Santra A, Kumar R, Sharma P, Bal C, Kumar A, Julka PK, Malhotra A. F 18 FDG PET CT in patients with recurrent glioma: comparison with contrast enhanced MRI. Eur J Radiol 2012;81:508-13.
14. Borbély K, Nyáry I, Tóth M, Ericson K, Gulyás B. Optimization of semi quantification in metabolic PET studies with 18F fluorodeoxyglucose and 11C methionine in the determination of malignancy of gliomas. J Neurol Sci 2006;246:85-94.
15. Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC 11C methionine PET for grading and prognostication in gliomas: a comparison study with 18F FDG PET and contrast enhancement on MRI. .
16. Yamaguchi S, Terasaka S, Kobayashi H, Narita T, Hirata K, Shiga S, Usui R, Tanaka S, Kubota K, Murata J, Asaoka K. Combined use of positron emission tomography with (18)F fluorodeoxyglucose and (11)C methionine for preoperative evaluation of gliomas. No Shinkei Geka 2010;38:621-8.
17. Tripathi M, Sharma R, D'Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A. Comparative evaluation of F 18 FDOPA, F 18 FDG, and F 18 FLT PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 2009;34:878-83.
18. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F FLT PET: comparison with 18F FDG. J Nucl Med 2005;46:945-52.
19. Enslow MS, Zollinger LV, Morton KA, Butterfield RI, Kadrmas DJ, Christian PE, Boucher KM, Heilbrun ME, Jensen RL, Hoffman JM. Comparison of 18F fluorodeoxyglucose and 18F fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 2012;37:854-61.
20. K arunanithi S, Shar ma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, Gupta DK, Malhotra A, Bal C. 18F FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F FDG PET/CT. Eur J Nucl Med Mol Imaging 2013;40:1025-35.
21. Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, Bal J, Pandey S, Kumar N, Mishra AK, Mondal A. Comparison of F 18 FDG and C 11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 2012;37:158-63.
22. Pötzi C, Becherer A, Marosi C, K aranikas G, Szabo M, Dudczak R, Kletter K, Asenbaum S. 11C methionine and [18F] fluorodeoxyglucose PET in the follow up of glioblastoma multiforme. J Neurooncol 2007;84:305-14.
23. Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta analysis. AJNR Am J Neuroradiol 2013;34:944 50, S1-11.
24. Raman A, Rothrock JF, Liu HG, Mountz JM. Differentiation of benign vs. malignant mass in a postirradiation cerebral arteriovenous malformation by 2 deoxy 2 [18F] fluoro D glucose positron emission tomography. Mol Imaging Biol 2004;6:1-6.
25. Polyzoidis KS, Miliaras G, Pavlidis N. Brain metastasis of unknown primary: a diagnostic and therapeutic dilemma. Cancer Treat Rev 2005;31:247-55.
26. Go KG, Pruim J, Que TH, Vaalburg W, Haaxma Reiche H. Evaluation of dissemination studies with FDG whole body positron emission tomography in patients with suspected metastatic tumours of brain and spine. Acta Neurochir (Wien) 2000;142:627-31.
27. Jeong HJ, Chung JK, Kim YK, Kim CY, Kim DG, Jeong JM, Lee DS, Jung HW, Lee MC. Usefulness of whole body (18)F FDG PET in patients with suspected metastatic brain tumors. J Nucl Med 2002;43:1432-7.
28. Klee B, Law I, Højgaard L, Kosteljanetz M. Detection of unknown primary tumours in patients with cerebral metastases using whole body 18F flouorodeoxyglucose positron emission tomography. Eur J Neurol 2002;9:657-62.
29. Campos S, Davey P, Hird A, Pressnail B, Bilbao J, Aviv RI, Symons S, Pirouzmand F, Sinclair E, Culleton S, Desa E, Goh P, Chow E. Brain metastasis from an unknown primary, or primary brain tumour? A diagnostic dilemma. Curr Oncol 2009;16:62-6.
30. Kyritsis AP, Levin VA, Yung WK, Leeds NE. Imaging patterns of multifocal gliomas. Eur J Radiol 1993;16:163-70.
31. Hanson MW, Glantz MJ, Hoffman JM, Friedman AH, Burger PC, Schold SC, Coleman RE. FDG PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991;15:796-801.
32. Kawai N, Miyake K, Nishiyama Y, Yamamoto Y, Miki A, Haba R, Imai T, Tamiya T, Nagao S. Targeting optimal biopsy location in basal ganglia germinoma using (11)C methionine positron emission tomography. Surg Neurol 2008;70:408-13.
33. Grosu AL, Pier t M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005;181:483-99.
34. Schaller B. Usefulness of positron emission tomography in diagnosis and treatment follow up of brain tumors. Neurobiol Dis 2004;15:437-48.
35. Santra A, Kumar R, Sharma P, Bal C, Julka PK, Malhotra A. F 18 FDG PET CT for predicting survival in patients with recurrent glioma: a prospective study. Neuroradiology 2011;53:1017-24.
36. Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M, Newlands ES, Swindell R, Matthews J, Price P. Early change in glucose metabolic rate measured using FDG PET in patients with high grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:331-8.
37. Bohndiek SE, Brindle KM. Imaging and 'omic' methods for the molecular diagnosis of cancer. Expert Rev Mol Diagn 2010;10:417-34.
38. Alkonyi B, Barger GR, Mittal S, Muzik O, Chugani DC, Bahl G, Robinette NL, Kupsky WJ, Chakraborty PK, Juhász C. Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of a 11C methyl L tryptophan PET. J Nucl Med 2012;53:1058-64.
39. Kumar A, Asano E, Chugani HT. A-[11C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies. Biomark Med 2011;5:577-84.
40. Arbizu J, Tejada S, Marti-Climent JM, Diez-Valle R, Prieto E, Quincoces G, Vigil C, Idoate MA, Zubieta JL, Pe-uelas I, Richter JA. Quantitative volumetric analysis of gliomas with sequential MRI and 11C-methionine PET assessment: patterns of integration in therapy planning. Eur J Nucl Med Mol Imaging 2012;39:771-81.
41. Bustany P, Chatel M, Derlon JM, Darcel F, Sgouropoulos P, Soussaline F, Syrota A. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11 L Methionine. J Neurooncol 1986;3:397-404.
42. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K. Diagnostic accuracy of 11C methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694-9.
43. Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, Herholz K. Use of 11C methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 2006;33:516-24.
44. Chiba Y, Kinoshita M, Okita Y, Tsuboi A, Isohashi K, Kagawa N, Fujimoto Y, Oji Y, Oka Y, Shimosegawa E, Morita S, Hatazawa J, Sugiyama H, Hashimoto N, Yoshimine T. Use of (11)C methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma. J Neurosurg 2012;116:835-42.
45. van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des 2008;14:3326-39.
46. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch Schmidtke R, Schwaiger M, Stöcklin G. Synthesis and radiopharmacology of O (2 [18F] fluoroethyl) L tyrosine for tumor imaging. J Nucl Med 1999;40:205-12.
47. Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, Sabel M, Steiger HJ, Reifenberger G, Beez T, Coenen HH, Floeth FW, Langen KJ. Diagnostic performance of 18F FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 2013;54:229-35.
48. Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F fluoro ethyl tyrosine (18F FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med 2012;53:207-14.
49. Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K. Analysis of 18F FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47:393-403.
50. Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, Sabel M, Langen KJ. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F] Fluoroethyl L tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 2013;40:22-33.
51. Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O (2 [18F] fluoroethyl) L tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-70.
52. Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nussbaumer K, Topakian R, Aigner RM. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 2010;37:1521-8.
53. Pichler R, Wurm G, Nussbaumer K, Kalev O, Silyé R, Weis S. Sarcoidois and radiation induced astrogliosis causes pitfalls in neuro oncologic positron emission tomography imaging by O (2 [18F] fluoroethyl) L tyrosine. J Clin Oncol 2010;28:e753-5.
54. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, Pietrzyk U. F Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996;37:1180-2.
55. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. Correlation of 6 18F fluoro L dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 2010;51:1532-8.
56. K arunanithi S, Shar ma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, Goenka A, Gupta DK, Malhotra A, Bal C. Comparative diagnostic accuracy of contrast enhanced MRI and (18)F FDOPA PET CT in recurrent glioma. Eur Radiol 2013;23:2628-35.
57. Saga T, Kawashima H, Araki N, Takahashi JA, Nakashima Y, Higashi T, Oya N, Mukai T, Hojo M, Hashimoto N, Manabe T, Hiraoka M, Togashi K. Evaluation of primary brain tumors with FLT PET: usefulness and limitations. Clin Nucl Med 2006;31:774-80.
58. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714-21.
59. Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T. Usefulness of FDG, MET and FLT PET studies for the management of human gliomas. J Biomed Biotechnol 2012;2012:205818.
60. Mertens K, Bolcaen J, Ham H, Deblaere K, Van den Broecke C, Boterberg T, De Vos F, Goethals I. The optimal timing for imaging brain tumours and other brain lesions with 18F labelled fluoromethylcholine: a dynamic positron emission tomography study. Nucl Med Commun 2012;33:954-9.
61. Huang Z, Zuo C, Guan Y, Zhang Z, Liu P, Xue F, Lin X. Misdiagnoses of 11C choline combined with 18F FDG PET imaging in brain tumours. Nucl Med Commun 2008;29:354-8.
62. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. Impact of 3,4 dihydroxy 6 18F fluoro L phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. J Nucl Med 2012;53:393-8.
63. Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, Herzog H, Shah NJ, Fink GR, Coenen HH, Langen KJ. Role of O (2 (18) F fluoroethyl) L tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med 2012;53:1367-74.
64. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, Grigg A, Callahan J, Hicks RJ. Comparative PET study using F 18 FET and F 18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci 2010;17:43-9.
65. Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougère C. MRI suspected low grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 2012;39:1021-9.
66. Floeth FW, Sabel M, Stoffels G, Pauleit D, Hamacher K, Steiger HJ, Langen KJ. Prognostic value of 18F fluoroethyl L tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med 2008;49:730-7.
67. Sato N, Inoue T, Tomiyoshi K, Aoki J, Oriuchi N, Takahashi A, Otani T, Kurihara H, Sasaki T, Endo K. Gliomatosis cerebri evaluated by 18Falpha methyl tyrosine positron emission tomography. Neuroradiology 2003;45:700-7.
68. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester HJ, Weber WA. An interindividual comparison of O (2 [18F] fluoroethyl) L tyrosine (FET) and L [methyl 11C] methionine (MET) PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 2011;81:1049-58.
69. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G. O (2 18F fluoroethyl) L tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high grade glioma. J Nucl Med 2011;52:856-64.
70. Heinzel A, Müller D, Langen KJ, Blaum M, Verburg FA, Mottaghy FM, Galldiks N. The use of O (2 18F fluoroethyl) L tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high grade glioma: a cost effectiveness analysis. J Nucl Med 2013;54:1217-22.
71. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. 18F FDOPA PET/MRI fusion in patients with primary/ recurrent gliomas: initial experience. Eur J Radiol 2009;71:242-8.
72. Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA. NCI sponsored trial for the evaluation of safety and preliminary efficacy of 3' deoxy 3' [18F] fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol 2009;11:343-55.
73. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. 18F FDOPA and 18F FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 2012;14:1079-89.
74. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. 3' deoxy 3' 18F fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 2012;53:29-36.
75. Idema AJ, Hoffmann AL, Boogaarts HD, Troost EG, Wesseling P, Heerschap A, van der Graaf WT, Grotenhuis JA, Oyen WJ. 3' Deoxy 3' 18F fluorothymidine PET derived proliferative volume predicts overall survival in high grade glioma patients. J Nucl Med 2012;53:1904-10.
76. Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC. 18F-FLT and 18F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging 2014;41:1199-209.
77. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res 2009;2:1-19.
78. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Pöpperl G, Holtmannspötter M, Kretzschmar HA, Kessler H, Tonn JC, Schwaiger M, Beer AJ. Imaging of integrin alpha (v) beta (3) expression in patients with malignant glioma by [18F] Galacto RGD positron emission tomography. Neuro Oncol 2009;11:861-70.
79. Hirata K, Shiga T, Fujima N, Manabe O, Usui R, Kuge Y, Tamaki N. (11)C Methionine positron emission tomography may monitor the activity of encephalitis. Acta Radiol 2012;53:1155-7.
80. Lee BY, Newberg AB, Liebeskind DS, Kung J, Alavi A. FDG PET findings in patients with suspected encephalitis. Clin Nucl Med 2004;29:620-5.
81. Mascarenhas NB, Lam D, Lynch GR, Fisher RE. PET imaging of cerebral and pulmonary Nocardia infection. Clin Nucl Med 2006;31:131-3.
82. Tsuyuguchi N, Sunada I, Ohata K, Takami T, Nishio A, Hara M, Kawabe J, Okamura T, Ochi H. Evaluation of treatment effects in brain abscess with positron emission tomography: comparison of fluorine 18 fluorodeoxyglucose and carbon 11 methionine. Ann Nucl Med 2003;17:47-51.
